$71M of revenue,
45% YoY growth,$350-370M full-
year guidance.
Amtagvi is selling. The growth ladder is built — if manufacturing keeps up.
↓ scroll to read
✦ The bottom line
Iovance's Q1 2026 revenue of $71 million was up 45% year over year — $60M from Amtagvi (lifileucel, the TIL therapy for advanced melanoma) and $11M from Proleukin. Full-year 2026 guidance is $350-370 million. That's not pre-commercial biotech math — that's a real launch ramping.
↓ the brief below
✦ Teach me
What 'TIL therapy' actually is
TIL stands for tumor-infiltrating lymphocytes — the patient's own T-cells, extracted from inside a tumor, multiplied in a manufacturing facility for weeks, then infused back into the patient. The promise: a one-time treatment that uses the immune system to attack solid tumors. Amtagvi (lifileucel) was the first TIL therapy ever FDA-approved (Feb 2024), for advanced melanoma after other treatments fail.
Wall Street calls this
Adoptive cell therapy
TIL therapy is genuinely first-in-class for solid tumors. If it can expand to more cancers (NSCLC, sarcoma, endometrial), the addressable market multiplies.
The top line · latest quarter
$71
M
Q1 2026 revenue of $71M, up 45% from $49M a year earlier — driven by U.S. Amtagvi sales of $60M and global Proleukin sales of $11M.
The bigger growth signal isn't the past quarter — it's the guidance. Management forecast Q2 revenue of $86-88M (a ~23% step-up over Q4 2025's pre-maintenance run-rate) and a full year of $350-370M. That's the company saying, *publicly, with a number*, that the launch is on its growth trajectory.
The commitment · FY2026 guidance
$350-370
M
FY2026 total revenue guidance of $350-370M — roughly 35% growth over FY2025's $263.5M, anchored by Amtagvi US expansion to 110+ treatment centers.